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tA pessimist sees the difficulty in every opportunity;
an optimist sees the opportunity in every difficulty.
—Sir Winston Churchill (1)
he U.S. health care system is under unprecedented pres-
ure for reform. Health care costs continue to rise and are
eemed unsustainable. The population is aging, and health
are needs are projected to increase. To add to the challenge,
he global economy is going through a difficult period.
owever, situations like these beget the best of creativity
nd enthusiasm. It is not surprising that multiple options of
ow to re-engineer health care delivery are being discussed.
lthough the alternatives are many and disparate, a com-
on element is the focus on improving health care quality.
idespread evidence of suboptimal overall care and the
ariations in care provided across both the hospital types
nd the geographical regions is difficult to dispute (2).
See page 1280
To effectively manage quality, there are 3 important
rerequisites. First, quality must be defined in a measurable
atrix. Second, there should be vehicles to measure the
uality matrix. Third, the root causes for the numerical facts
hould be understood. Without adequately addressing all 3
acets, effective intervention development and implementa-
ion is difficult. To move the quality notion from a meta-
hysical to a measurable paradigm, quality measures for
arious diseases are being defined. The American College of
ardiology and the American Heart Association have
efined heart failure performance measures that include
arfarin use in patients with chronic or recurrent atrial
brillation (3).
To measure and manage these indicators, various forms
f registries have come into existence. In this issue of the
ournal, Piccini et al. (4), using one such registry, the
merican Heart Association’s Get With The Guidelines
GWTG) Heart Failure Registry, provide insights into the
se of anticoagulation for atrial fibrillation in heart failure
atients. The results are both important and sobering. The
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From Emory University, Atlanta, Georgia. Dr. Butler serves as the Deputy Chief
cience Advisor for the American Heart Association. All perspectives in this editoriali
re the authors’ views and do not necessarily reflect either the American Heart
ssociation or Emory University’s standpoint.nvestigators report that warfarin use was suboptimal, that it
id not improve over time, that there was substantial
egional variation in use, and interestingly, that warfarin use
as inversely related to the CHADS2 (congestive heart
ailure, hypertension, age, diabetes, prior stroke or transient
schemic attack) risk score. This study underscores the
otential of large registries for improving health care,
ecause individual hospital data are unlikely to give this
etailed insight. It is possible, and very likely, that this study
ill lead to development of quality improvement interven-
ions that will hopefully improve on the current trends.
Are all of the conclusions of this study justified? Regis-
ries are snapshots of real life and should be interpreted as
uch. Interpreting registry data with approaches and terms
temming mainly from clinical trials and cohort studies is
nlikely to provide insights that will help improve quality of
are. In their study, Piccini et al. (4) encountered a situation
ommonly observed in registries, that is, aggressiveness of
reatment decreases as risk increases. This seems paradoxical
nd alarming at first. However, in most such instances, only
isk is measured formally, for example, with the CHADS2
core for atrial fibrillation. Unfortunately, the physical,
ental, and social vulnerabilities, all strongly associated
ith risk, are usually not systematically recorded. The
edian age of patients with atrial fibrillation in this study
as 79 years, yet common geriatric problems such as
ognitive impairment, fall risk, dizziness, visual distur-
ances, and so on, and dependency in activities of daily
iving were not recorded. This probably reflects the fact that
hese conditions are not part of the traditional medical
odel and thus are not common targets in the current
ystem of health care. In line with the traditional model,
ligibility for warfarin treatment was defined by lack of
ormal contraindications. However, up to 50% of individu-
ls ages 65 years or older have 1 or more geriatric conditions,
nd a sizable proportion are dependent on others for their
xtended needs (5). These and other forms of vulnerability
ay reduce an older person’s ability to participate in their
are; this is especially important for oral anticoagulation and
ay have affected the physician’s decision to start warfarin.
hus, before concluding that physicians failed to start
arfarin in 1 of 3 eligible patients, it might be prudent to
onsider and ideally to record these real-life issues. Indeed,
he fact that despite regular feedback there was no trend in
mprovement over 3.5 years is telling us something!
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September 29, 2009:1290–2 Registries and Health Care Quality ImprovementSo how do we measure health care delivery and quality
ata? In this respect, the last decade has seen a rapid
roliferation of registries with rapid growth in both num-
ers and scope. These include registries operated by volun-
ary health and patient advocacy organizations, for example,
WTG registries by the American Heart Association;
rofessional organizations such as the National Cardiovas-
ular Data Registry by the American College of Cardiology;
nd the pharmaceutical industry, for example, the Acute
ecompensated Heart Failure National Registry. The im-
act of these registries in understanding the disease process,
ontemporary epidemiology, racial and sex disparities, and
reatment trends, and their impact on influencing guide-
ines, are too numerous to cite. Most importantly, they are
reat tools for managing evidence-based medicine and
mprove quality of care.
Registries have evolved over time. Starting with primarily
ndividual hospital-based operations to later regional and
hen national initiatives, registries evolved from paper-based
ools requiring manual data entry to sophisticated software
ools that can communicate with electronic health records.
rom an intermittent individual look at the data, these have
atured to generate periodic comparative reports. Ad-
anced features such as decision support tools, real-time
eporting and benchmarking, and customization for inquiry
nd reporting are featured in several registries already, for
xample, the GWTG registry. The evolution, as impressive
s it has been, is not perfect. Despite their success, we
elieve that the future evolution of registries needs to
onsider the following.
eveloping smarter registries. With the proposed gov-
rnmental support in the American Recovery and Reinvest-
ent Act, the use of electronic health records will likely
ncrease. This may directly or indirectly increase the scope
nd participation in registries. However, these registries
ust go beyond mere data collection tools and move from
iscovering numerical truths to understanding the root
auses behind the numbers. Can we have device registries
ith real-time data collection to understand the rationale
or medical decision making? It is impossible to design
ractically feasible registries with an exhaustive list of
nquiries; however, point-of-care data collection to capture
edical decision rationale is certainly possible. Without
nderstanding the “why” behind the trends, the implicit
ssumption is that variation is related to simple explanations
uch as not remembering to prescribe, but the reality is more
omplicated. Health care quality literature is perpetually
lagued by lack of a true denominator, that is, how many
atients were truly eligible for certain treatment options.
easons why physicians do not follow guidelines are com-
licated. Without understanding the root causes, designing
ffective interventions is difficult. The current study is one
xample. Do we just take it at face value that physicians use
ess anticoagulation when the risk of stroke is higher?
erhaps we should give more credit to the physicians. Ateast part of these trends may be explainable by data not uaptured in registries. Thus, registries that go beyond the
sual fact determination to understanding reasons behind
ecisions will be immensely useful.
andatory registries! There is an aversive reaction to
andating anything in medicine. However, as we restruc-
ure health care and build in more incentives for quality
mprovement, participation in registries may increase. In
ertain cases, for example, left ventricular assist devices, the
ery nature of the therapy precludes enrollment of large
umbers of patients in randomized trials before approval.
erhaps mandating participation in certain registries is
ustifiable because this will be the only way to learn
ppropriate patient selection and management strategies.
evelop a business case for registries. Development and
mplementation of an infrastructure for registries can be
xpensive. Participating in registries at the hospital or
ractice level may not be very costly and usually requires
ominal participation fees and salary support for personnel
o submit data. In the current health care environment,
dding any costs will be scrutinized and likely rejected.
owever, the return on investment in terms of real-time
ata, opportunities for intervention implementation, and
nancial incentives for quality improvement may make it
ttractive to participate in registries. For the up-front cost of
nitiating registries, those that are funded by specific exter-
al sources may not have the leverage to be conducted in the
ost beneficial and unbiased manner. Thus, a business case
or registries needs to be developed. These may include cost
hifting from other less productive medical endeavors; cost
haring between providers, payers, or vendors; or other alter-
atives. Ideally, we may assign a value system to registries based
n their need and benefit; however, the current economic
nvironment will likely not support such a notion.
lectronic health records and registries. Although cur-
ently it may not be costly to participate in any individual
egistry, costs add up when participating in multiple regis-
ries. As the push for improving quality of care accelerates,
t is likely that registries will be developed for multiple
isease states. Personnel support for data extraction and
ubmission for all such initiatives can be expensive. Thus
nvestment in electronic health records in which the data-
ase may be programmed to extract data for various mea-
ures for different disease states is likely to provide the best
ption.
egistries as marketing tools. Without an independent
usiness model, registries may often be funded by entities
ith a vested interest. Caution is needed to not have the
ommercial aspects guide the content and conduct of
egistries, which may lead to losses in both the data content
nd credibility.
ata sharing. Registry and clinical trial databases in many
ases are not easily accessible. Considering the costs and
ffort needed to collect these data, one can understand such
dynamic. However, in certain cases this can lead to
nnecessary obstacles in analyzing the data that could be
sed for public good. Rapid analysis and dissemination of
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Registries and Health Care Quality Improvement September 29, 2009:1290–2nformation should be encouraged. One may even argue
hat at the time of individuals consenting to allow access to
heir data for trials and registries, or when obtaining a
aiver of consent by the institutional review boards, it is not
pelled out explicitly that data access will be limited. A
ommon concern cited is to ensure the database and analysis
redibility, which might not be possible with widespread
ata distribution. However, this is manageable. There are
xamples of National Institutes of Health-sponsored studies
hat can be accessed by any investigator, but there are
afeguards placed against misuse, including analytic plan
nd manuscript reviews by specific committees before jour-
al submission. Similarly, complying with certain privacy
ules is another hurdle. Any attempt that increases rapid
ata dissemination for public good should be encouraged.
egistries are not substitutes for randomized control
rials. One must caution regarding the use of registry data
o generate evidence. Medical literature is full of association
tudies from databases that do not hold up in randomized
rials. There are no statistical tools that can control for
nmeasured confounding. Registries are great for managing
vidence-based medicine developed by randomized clinical
rials, but not for replacing them.
With appropriate safeguards, widening horizons, utiliza-
ion of electronic and web capabilities, and government
upport for electronic health records, and by creating sound
usiness models, the use and usefulness of registries will Kontinue to evolve and expand. In the meantime, Piccini et
l. (4) should be congratulated on their work and we should
o back to the drawing board to figure out the root causes of
uboptimal utilization and how to optimize anticoagulation
n heart failure patients with atrial fibrillation.
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